
Background The Togolese government has been committed to ensuring universal health coverage since 2012 through a stepwise process. Multiple reforms have been implemented to achieve universal primary healthcare, in line with the World Health Organization's recommendations and the Alma-Ata commitment. Aim This paper assesses the core capacities of the Togolese health system to deliver UHC and, as a corollary, identifies potential gaps and requirements in HSS necessary for implementing UHC. Results The country spends 6.7% and 5.6% of GDP on total and current health expenditures, respectively. The Domestic General Government Health Expenditure (GGHE-D) accounts for only 2.6% of the government's total budget, 9.8% of current health expenditure, and 0.54% of GDP. The health system relies heavily on funding from foreign agencies, which accounts for 15.8% of current Health expenditure. The private sector accounts for the largest share of financing (70.6%), with 65.9% of current health expenditures paid out of pocket. The health insurance scheme accounts for only 8% of current health expenditures and covers approximately 7.5% of the population. In this system, there is one (1) physician for 16,191, one (1) nurse for 6430, and one (1) midwife for 10,069 inhabitants. Most medical products are imported, and the country faces a brain drain phenomenon among its healthcare staff. Conclusion The Togolese health system's financing and stewardship are weak, inequitable, and unsustainable. This extends to the rest of the health system, including service provision and resource generation, which makes achieving universal health coverage very challenging.
Super-speciality medical education in India has expanded rapidly over the past four decades, increasing from fewer than 100 seats in the 1980s to more than 5000 DM/MCh/DrNB seats by 2025. This growth reflects advances in diagnostics and surgical technology, as well as the rising burden of complex non-communicable diseases. Up to 45–58% of tertiary visits involve conditions manageable at primary levels, while rural regions face severe shortages of super-specialists, with 80–85% of specialists concentrated in urban districts. Private multispeciality hospitals host most high-skilled professionals, reinforcing geographic and sectoral inequities.Training quality also varies widely due to faculty shortages, commercialisation, and inconsistent regulatory enforcement. Emerging disciplines such as genomics, metabolic medicine, and precision medicine remain poorly integrated within siloed DM/MCh structures.This critical narrative review synthesised peer-reviewed literature, regulatory documents and national datasets published between 1980 and 2025, identified through a structured search and analysed using the World Health Organization (WHO) health system building blocks framework. The review argues for restructuring India's medical education and service delivery architecture by strengthening general practice, enforcing referral pathways, and standardising training quality. A cluster-based model linking primary care, secondary hubs, and tertiary precision centres is proposed, with reform pathways organised across all six building blocks, to align super-speciality expertise with population needs. Because the evidence relies heavily on a small number of apex institutions and states and on grey literature, the findings should be interpreted with caution.
Introduction The Egyptian health care system is undergoing significant transformation towards universal health coverage, and it is, therefore, necessary to evaluate the sustainability and resilience of the health system financing. Aim Our study aims to analyze the sustainability and resilience of health system financing in Egypt and provide evidence-based recommendations for evidence-informed policymaking. This was achieved through: (1) studying the current financing mechanisms of Egypt's health system; (2) determining how sustainable are these financing mechanisms given current trends; and (3) evaluating how resilient was the Egyptian health system financing during the COVID-19 pandemic. Methods The study was conducted from July 2023 to December 2023 over three stages: (1) literature review, (2) semi-structured interviews with 16 key stakeholders, and (3) focus groups with 12 experts. We conducted qualitative data analysis using a framework analysis approach, with findings triangulated across the three data sources. Narrative synthesis was used to summarize the main findings. Findings The health system in Egypt is currently financed through the old health insurance system, the newly implemented universal health insurance (UHI) system, private insurance system, and out-of-pocket financing. Financial indicators showed improved sustainability of health financing. Between 2010 and 2020, Egypt's health spending as a percentage of GDP increased, while out-of-pocket spending as a percentage of current health expenditures decreased. However, significant structural challenges persist, including a heavily regressive financing structure and coverage gaps for vulnerable populations. The UHI program ensures sustainability of health financing for the whole population in the longer term. Key insights demonstrated the resilience of the Egyptian health system financing during the COVID-19 pandemic, where supplementary public funds were released to cover the additional pandemic-related expenditures. Conclusion: This study provides valuable insights and evidence-based recommendations for policymaking to promote the sustainability and resilience of health system financing in Egypt. Recommendations are organized by health system sustainability and resilience domains and explicitly linked to policy implications to support evidence-informed policymaking.
Background The reimbursement of high-impact medicines (HIMs) poses growing clinical and budgetary challenges for publicly funded health systems. In Catalonia, pharmaceutical spending has increased considerably in recent years, driven by the uptake of high-cost therapies and expanded indications under clinical and economic uncertainty. To mitigate these risks, payers have increasingly used managed access mechanisms in reimbursement strategies. Objective To assess the economic impact of newly reimbursed high-impact medicines in Catalonia and describe the role and economic implications of managed access mechanisms applied to address clinical and financial uncertainty. Methods We conducted a retrospective study using real-world data from Catalonia's health service registries and billing systems. Expenditure trends for HIMs between 2019 and 2024 were analysed. Newly reimbursed indications from 2022 to 2024 were evaluated by therapeutic class, volume of patients, and aggregated expenditure per patient, taking into account the managed access mechanisms applied. Results From 2019 to 2024, HIM expenditure rose by 53% in nominal terms, from €1.10 billion to €1.69 billion; after adjustment for inflation, 2019 expenditure corresponded to approximately €1.30 billion in 2024 euros, indicating a real increase of approximately 30%. In 2024, HIM expenditure represented about 11% of the total healthcare expenditure managed by the Catalan Health Service. The top 10 medicines accounted for 43% of expenditure. Newly reimbursed indications in 2024 represented €23.6 million. Managed access mechanisms were applied to nearly three-quarters of these indications, including indication-based restrictions and formal agreements. Formal managed access agreements included confidential discounts, spending caps, patient-level spending caps, free-dose schemes, price–volume agreements, outcome-based payment models, and staggered payments. Conclusions Newly reimbursed HIMs exert concentrated expenditure pressure. These findings illustrate how the broad use of managed access mechanisms can support balancing access to innovation with health system sustainability. Future research is needed to identify the most effective managed access strategies to facilitate access to new HIMs at costs sustainable for health systems.
Background Quality monitoring ensures quality standards and improvement, while public reporting aims to inform patient choice. In Switzerland, quality monitoring and public reporting have fallen short of stakeholder expectations due to a misalignment with needs. Objectives This study explores stakeholder needs in inpatient and outpatient care for public reporting and quality monitoring in Switzerland. Methods In 2023, nine focus groups with 50 stakeholders from in- and outpatient somatic care were conducted. The data underwent qualitative content analysis to identify themes related to the purpose, challenges, and drivers of public reporting and quality monitoring, as well as indicator selection criteria. Results Public participants emphasised accessible quality information to guide decisions, especially in chronic or serious illness. A major gap was a single point of contact for navigating care and shared decision-making. Public and expert views diverged on who should access and interpret quality data. Experts prioritised monitoring for internal improvement. Both groups cited administrative burden and system fragmentation as key barriers. Conclusion While patients seek more involvement and access to data, expert reluctance to share quality information persists. Advancing public reporting requires recognising the public as a core audience and addressing data challenges through a national strategy.